{Reference Type}: Case Reports
{Title}: Eculizumab in the Treatment of Gemcitabine-Induced Atypical Hemolytic Uremic Syndrome.
{Author}: Azad F;Miranda CJ;Amin A;Hadwani R;Gravina M;
{Journal}: Cureus
{Volume}: 15
{Issue}: 3
{Year}: Mar 2023
暂无{DOI}: 10.7759/cureus.35874
{Abstract}: Gemcitabine-induced hemolytic uremic syndrome is an often-missed condition. We present a case outlining the successful management of a patient with metastatic cholangiocarcinoma treated with gemcitabine who subsequently developed hemolytic uremic syndrome. Early recognition and stopping gemcitabine are essential in this patient population. Complement inhibitors have been used, and our patient improved on eculizumab therapy.